Cancer Drug Truxima Receives License for Distribution in Colombia

In an extension of its partnership with Celltrion Healthcare, pharmaceutical provider Mundipharma has received a license to market and distribute its Truxima cancer treatment drug in Colombia.

Truxima was also launched as the first “biosimilar monoclonal antibody” licensed for the treatment of cancer in various European markets in February, according to the Singapore-headquartered network of drug companies.

Mundipharma added that it is widely authorized in Europe for the treatment of diffuse large B cell Non-Hodgkin’s lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, and granulomatosis with polyangiitis and microscopic polyangiitis.

Raman Singh, chief executive officer of Mundipharma, said that this is a continuation of the firm’s push to distribute its drugs in new markets. “We are excited to expand our partnership with Celltrion Healthcare to include Truxima in Colombia,” said Singh. “As a core therapy for hematological malignancies, we see it as a good fit with our existing potfolio of products such as Difolta and Zevalin.”

(Photo credit: jarmoluk / Pixabay)